Sir,

We hereby report a case of severe extravasation following peripheral IV administration of potassium chloride (KCl) under general anesthesia (GA). A 52-year-old woman with epithelial ovarian cancer was scheduled for surgical debulking. The patient did not receive chemotherapy before surgery and had good venous capital. Before induction, a peripheral intravenous (IV) double-lumen catheter 20 Ga (Arrow Twin-Cath® 20/22) on the latero-external side of the left wrist was successfully obtained. After induction, a second IV access was obtained with a 20 Ga catheter (Vasofix^®^ Braunule^®^) inserted on the posterior side of the left arm. Forced air-warming blanket covering the upper body and the arms was used to maintain normothermia. The procedure lasted 8 h. Intraoperative course was uneventful except for severe hypokalemia of 2.7 mEq.l^-1^. We started KCl 10% 10 mEq.l^-1^ using an infusion pump (Perfusor^®^ compact, B/Braun, Melsungen AG, Germany) over the second IV line directly without perfusion, for 3 h. The anesthetist nurse checked the IV lines every 30 min. At the end of the procedure, the forced air-warming blanket was removed, and a severe IV extravasation was noted \[[Figure 1a](#F1){ref-type="fig"}\]. Infusion was stopped, aspiration from the catheter was attempted, then the line was removed. The left arm was elevated, and cold gauzes were applied. In the recovery room, the patient complained of severe pain in her left arm. Plastic surgery was consulted and advised local application of MEBO^®^ (Moist Exposed Burn Ointment) burn ointment four times daily. The lesion extended on postoperative days 1 and 2 \[Figure [1b](#F1){ref-type="fig"} and [c](#F1){ref-type="fig"}\]. Regular follow-up showed improvement of local skin perfusion, good healing was seen, and skin necrosis was prevented. She was fully recovered after 3 months \[[Figure 1d](#F1){ref-type="fig"}\].

![Extravasation injuries at (a) the end of surgery, (b) postoperative day 1, (c) postoperative day 1, and (d) after 3 months](SJA-13-397-g001){#F1}

The severity of tissue injury depends on the type, concentration, and quantity of the injected vesicant agent and the infusion rate. Patients with small vessels such as diabetics or atherosclerotics; the elderly and children were at increased risk. Additional risk factors are improper insertion site over a flexion area, traumatic insertions causing damage to the internal lining of the vessel, obstructions to blood flow through the catheter, and incorrect device selection for the drug. Extravasation is a serious complication because it induces a chain reaction of inflammation and tissue damage that could last for weeks or months. Delayed recognition and management or mismanagement might have serious consequences from scarring, damage to the underlying tendons and nerves, contracture, marked soft skin tissue loss requiring skin grafting to amputation, and permanent disability.\[[@ref1][@ref2]\] Case reports of devastating tissue injuries following cisplatin, phenytoin, antibiotics, diuretics, and dextrose extravasation required reconstructive surgery.\[[@ref3][@ref4][@ref5]\]

In our case, the damage owing to extravasation of KCl into the surrounding tissue was severe. The main determining factors were GA (loss of pain sensation), type of drug (KCl) with vesicant properties, direct infusion using a pump through the vasofix, and lack of visibility of extravasation. Following this incident, we recommended administering of vesicant medications over a 3-way stopcock with fluid perfusion because slowing or stopping of the infusion were alert signs, keeping continuous visibility of IV access in a patient under GA.

In conclusion, extravasation injury can lead to serious complications. It can increase morbidity and cause long-term sequelae. As with most complications, prevention was always the best measure.
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